

Nucleobase coupling by Mitsunobu reaction towards nucleoside analogs

Eduardo C. de Sousa and Amélia P. Rauter

*Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa
Ed C8, Piso 5, Campo Grande, 1749-016 Lisboa, Portugal
Email: aprauter@fc.ul.pt*

This paper is dedicated to Prof. Dr. Horst Kunz on the occasion of his 80th anniversary


Received 09-21-2020

Accepted Manuscript 11-29-2020

Published on line 12-20-2020

Abstract

The coupling of a nucleobase is a key step in the synthesis of most nucleoside analogs, e.g. carbocyclic nucleosides, isonucleosides and acyclic nucleosides. The synthetic strategies for nucleosides based on *N*-glycosylation are not applied when the nucleobase is not linked to the anomeric center. Thus, other methods have been employed, mainly those based on the alkylation of nucleobases. The Mitsunobu reaction, in which a hydroxy group is replaced by a nucleophile, has also been extensively applied, generating a diversity of molecules, including pharmaceuticals and their precursors. In this review the usefulness of this reaction for the coupling of nucleobases to non-anomeric positions of sugars, carbasugars and other homocyclic and linear structures is highlighted and discussed, covering purines and pyrimidines as pronucleophiles.



Keywords: Mitsunobu reaction, carbocyclic nucleosides, isonucleosides, acyclic nucleosides, synthesis


Table of Contents

1. Introduction
 - 1.1. Nucleoside analogs
 - 1.2. Mitsunobu reaction
 2. Nucleobase Coupling
 - 2.1. Reaction conditions in MR and alcohol structure
 - 2.2. Regioselectivity, side reactions and product purification
 - 2.3. MR as an alternative to nucleobase coupling failure
 3. Purine Coupling
 - 3.1. Adenine and adenine precursors' coupling
 - 3.2. Guanine precursors' coupling
 - 3.3. Regioselectivity and alkylation of purine amino groups
 4. Pyrimidine Coupling
 - 4.1. N¹/O-2 Regioselectivity
 5. Coupling of Other Nitrogen Heterocycles
 6. Microwave-assisted MR Coupling
 7. Conclusions
- References

1. Introduction

1.1. Nucleoside analogs

Nucleosides and nucleotides have been extensively used as prodrugs in antiviral and cancer chemotherapies. Nucleoside analogs comprise often a nucleobase coupled to the anomeric position of a modified carbohydrate moiety and act as inhibitors of nucleic acid synthesis. After entering the cells through specific transporters, they are phosphorylated, leading to the accumulation of nucleotide analogs in cancer or virus-infected cells. These mono-, di- and triphosphorylated nucleotide analogs act by inhibiting intracellular enzymes, or by incorporating the synthesized DNA and RNA, inducing DNA chain elongation termination, apoptosis or mutations in viral progeny.^{1,2} Nucleoside analogs, namely those with carbasugars or acyclic moieties linked to the nucleobase, or with the nucleobase coupled to a non-anomeric position of the carbohydrate (isonucleosides) have been extensively studied. Recently, a comprehensive review was published covering the chemical synthesis of azasugar, thiosugar and selenosugar nucleosides and their anticancer activity.³ Both carbocyclic and acyclic nucleosides find application as antiviral drugs, e.g. the carbocyclic nucleoside entecavir and acyclovir, an acyclic nucleoside (Scheme 1). There are also reports of antiviral isonucleosides, e.g. the antiherpetic BMS 181,164, developed by Bristol-Myers Squibb (BMS)^{4,5} but, as far as we know, they do not include the clinically available drugs for the management of viruses.



Scheme 1. Structure of deoxyguanosine mimicking antiviral drugs entecavir (carbocyclic nucleoside), acyclovir (acyclic nucleoside) and the isonucleoside BMS 181,164, developed by Bristol Myers and Squibb (BMS).


The absence of a *N*-glycosyl bond, which can potentially increase the stability in a biological environment,⁶ poses a problem: the coupling of the nucleobase to the sugar mimetics or to a non-anomeric position cannot be accomplished by reactions carried out for nucleoside synthesis that take advantage of the specific reactivity of the anomeric center. Therefore, key synthetic strategies must be employed to obtain the nucleoside analog. The most common approaches can be classified into two groups: nucleobase coupling and nucleobase building-up. In the first strategy the desired nucleobase (or a precursor) is coupled directly to the sugar (or sugar mimetics), while in the latter, the nucleobase is constructed from a linear (for pyrimidines) or aromatic (for purines) structure, already linked to the sugar. The coupling of the nucleobase can be achieved by a variety of methods.^{7,8} One of them makes use of the Mitsunobu reaction (MR), as illustrated and discussed in this review for the synthesis of nucleoside analogs.

1.2. The Mitsunobu reaction

First reported in 1967,⁹ this reaction has a diversity of synthetic applications as described in comprehensive reviews published in 2009¹⁰ and 2015.¹¹ MR conducts to the replacement of the substrate free hydroxy group by a nucleophile, with inversion of configuration when the substrate is chiral, mediated by dialkyl azodicarboxylate and trialkyl- or triarylphosphane. The reaction requires the activation of dialkyl azodicarboxylate with the phosphane leading to the formation of betaine **1**, which reacts with the pronucleophile (NuH) generating the ionic species **2**. Reaction with the alcohol gives a phosphonium salt and ethyl 2-(propionyloxy)hydrazinecarboxylate (**3**). The attack of the nucleophile follows a S_N2 mechanism to afford the final product and trialkyl- or triarylphosphane oxide,¹⁰⁻¹² as shown in Scheme 2, for a reaction mediated by diethyl azodicarboxylate (DEAD) and triphenylphosphane. Interestingly, a S_N1 mechanism can take place, but is very rare and was never reported to occur in nucleobase coupling.¹⁰ The pronucleophile usually comprises a -OH, -SH or -NHR group, although other groups with a pK_a lower than 11 may also react.¹¹ The common azodicarboxylates in MR are DEAD and diisopropyl azodicarboxylate (DIAD), di-*tert*-butyl azodicarboxylate (DBAD) is also used, while triphenylphosphane is, indeed, the most frequently phosphane applied.

Catalytic MRs should also be highlighted, as they overcome MR issues such as poor atom economy, and the formation of stoichiometric phosphane oxide and/or hydrazine by-products. Aiming at reducing to a catalytic amount the azo MR reagent, Toy *et al.*^{13,14} used iodobenzene diacetate to reoxidize the hydrazine formed, while Hirose *et al.*^{15,16} described the first MR in which hydrazine is reoxidized in the presence of a catalytic amount of iron phthalocyanine and atmospheric oxygen. The first fully catalytic MR was reported by Buonomo & Aldrich,¹⁷ who used catalytic 1-phenylphospholane, employing phenylsilane to recycle the catalyst, integrating it with Taniguchi's azocarboxylate catalytic system. One year later, Hirose *et al.*¹⁸ reinvestigated this reaction and in 2016 they reported examples for which the catalytic system in phosphane

reagent is incompatible with that in the azo reagent. Recently, a fully catalytic redox-free MR has been reported¹⁹ using (2-hydroxybenzyl)(methyl)(phenyl)phosphane oxide as catalyst. The oxidation state of phosphorus remains +5 all over the reaction, as the mechanism involves the formation of a phosphonium ring with the oxygen of the phenol hydroxy group linked to phosphorus, which is opened by the alcohol. This reaction has been successful for C-O, C-N and C-S bond formation, leads to inversion of configuration, does not involve stoichiometric oxidant nor reductant, and has water as the single by-product.¹⁹ To the best of our knowledge, catalytic MR reactions have not yet found application for the synthesis of nucleoside analogs.



Scheme 2. Mechanism for the Mitsunobu reaction.¹²

In nucleoside analog synthesis, the nucleobase acts as a pronucleophile and replaces the hydroxy group of the substrate. Therefore, this synthetic strategy is more efficient in a single unprotected hydroxy group, although steric hindrance may affect the reactivity of some hydroxy groups, resulting in regioselectivity.²⁰ The nucleobase also has an impact on the outcome of the reaction as further discussed in this review.

MR has seen extensive use for nucleobase alkylation, mostly in the context of drug development, including scale up attempts, namely for the synthesis of the antiviral drug entecavir, in gram^{21,22} and even kilogram²³ scales. The application of MR in large scale has so far been limited by the complex nature of the resulting reaction mixtures, which makes them difficult to purify. However, the methodologies based on catalytic Mitsunobu reactions seem to solve this issue.^{19,24}

2. Nucleobase Coupling


The effectiveness of the nucleobase coupling by MR depends on the alcohol precursor, the nucleobase and the reaction conditions, namely the solvent, the temperature and the order in which the reagents are added.²⁵⁻²⁸ The usual yield of a nucleobase coupling reaction through MR is in the 50% to 80% range, for carbasugar, other carbohydrates and acyclic substrates, with higher yields being generally obtained with primary alcohols. The low reactivity of the alcohol, a lack of regioselectivity, side reactions and the difficulty in purification of the complex reaction mixture may also compromise reaction yields.^{29,30} Nonetheless, MR is a suitable and unique alternative to some nucleoside analogs that could not be synthesized by the usual

methodologies and has proven appropriate for the coupling of purines and pyrimidines as described in sections 3 and 4 of this review.

2.1. Reaction conditions in MR and alcohol structure

In carbocyclic nucleoside and isonucleoside synthesis the limiting reagent is the alcohol, while for acyclic nucleosides it is common to use an excess of alcohol in relation to the nucleobase.^{26,28,31-34} This excess may have to be handled in different ways, as demonstrated by Lu *et al.*³¹ Aiming to overcome low yields caused by alcohol degradation, two successive additions of the non-limiting reagents (alcohol, DIAD and PPh₃), separated by 6 hours, were made, resulting in a considerable yield increase. Similar procedures have also been successfully used by other authors.^{26,34}

The influence of alcohol structure on reaction yield is clearly demonstrated by Šála *et al.*³⁵ during coupling of 6-chloropurine with bicyclic alcohols **4**, **5**, **6** and **7** (Scheme 3) via MR protocol. While the yield was higher with a primary alcohol, resulting from less steric hindrance, those for the secondary alcohol substrates were considerably different, with the highest yield obtained for alcohol **5**. Lu *et al.*,³¹ Dai *et al.*³² and Fletcher *et al.*³³ used *tert*-butanol as a model tertiary alcohol but no reaction occurred, while the other alcohols screened gave yields in the 80-90% range, with the nucleobase as the limiting reagent. This was expected as MR reacts mainly via S_N2 mechanism.



Scheme 3. MR coupling of 6-chloropurine to different bicyclic alcohols as reported by Šála *et al.*³⁵

However, there are alcohols where MR coupling did not succeed, even when several reaction conditions were explored. Few such examples are reported in the literature by Chen *et al.*³⁶ during assembly of fluorinated acyclic nucleoside phosphonates containing cytosine and adenine, by Brémond *et al.*³⁷ and Kasula *et al.*³⁸ in an attempted synthesis of aristeromycin analogs embodying 6-chloropurine and 7-deazapurine moieties, respectively. Rosen *et al.*³⁹ also failed the coupling of cytosine and 2-amino-6-chloropurine to mono-fluorinated cyclopropane sugar mimetics. The alternative pathway was based on the conversion of the free


hydroxy group into e.g. mesylate or tosylate, followed by the conventional S_N2 reaction to couple the nucleobase, in two reaction steps.

The solubility of the nucleobase can also have a noticeable effect on the outcome of the reaction. While a variety of solvents can be used for MR,¹⁰ the most frequently used for nucleobase coupling is THF. The low solubility of nucleobases such as adenine⁴⁰ and N^4 -benzoyl cytosine⁴¹ in this solvent have hampered their use in MR. One good example of the importance of nucleobase solubility is given by Bazile *et al.*⁴² who found out that the yield of MR coupling of 2-fluoroadenine, which has low solubility in THF, was low (only 27%), while that for the coupling of its Boc-protected derivative was 88%.

2.2. Regioselectivity, side reactions and product purification

The reaction conditions affect the regioselectivity during coupling to purines (N^9/N^7) and to pyrimidines ($N^1/O-2$); however, this is mainly an issue for pyrimidines, which rarely lead to a single product, while MR with purines leads mostly to N^9 ligation; moreover, the N^3 position of uracil and thymine pronucleophiles is protected in most cases to prevent the formation of N^3 and O-4 linked nucleoside analogs.


The formation of side products is also frequent, resulting in low reaction yields. In carbasugars embodying an α,β -unsaturated alcohol, e.g. in compound **8** (Scheme 4), the β -addition of the nucleobase, migration of the double bond and displacement of triphenylphosphane oxide can also take place.⁴³⁻⁴⁵ Scheme 4 illustrates the results obtained by Kumamoto *et al.*,⁴⁵ who was able to prepare nucleoside **10** in only 26% with the concomitant formation of the analog diastereoisomers **9a,b**, obtained in 41% yield. This effect was mitigated by replacing $-C\equiv CH$ by $-CO_2Me$, resulting in the formation of only the desired product **12** in 58% yield.⁴⁵



Scheme 4. Nucleophile β -addition side reaction, as reported by Kumamoto *et al.*⁴⁵

Another reported side reaction is dehydration of alcohol precursor. Both Viña *et al.*⁴⁶ and Weising *et al.*²⁹ experienced this problem when attempting to synthesize *cis* carbocyclic nucleosides (Scheme 5); in the latter case, a relationship between solvent used and the extent of elimination was found, since reactions in MeCN resulted in more elimination than those in THF. Dehydration may also occur in linear alcohols, as shown by

Guo *et al.*;²⁷ in this case, the elimination reaction occurred when the L-serine amino group was protected by Boc, while the same was not verified with a trityl protecting group.




Scheme 5. Alcohol dehydration, as reported by Viña *et al.*⁴⁶ (A), Weising *et al.*²⁹ (B) and Guo *et al.*²⁷(C).

Product purification is also a challenge.^{29,47-52} MR reaction mixture is usually quite complex, containing remaining excess reagents, the dialkyl hydrazine-1,2-dicarboxylate derivative, triphenylphosphane oxide, the desired product and, in some cases, also side products. Therefore, tedious purification processes result in low product yields.⁵⁰ One solution practiced is the use of crude products in the following step, leading to separable products.^{49,51} Also investigation of other appropriate nucleobases may be a strategy towards nucleoside analog purification.⁴⁸


2.3. MR as an alternative to nucleobase coupling failure

Common nucleobase coupling strategies are not efficient for all target molecules, and MR can be the appropriate alternative, as shown by Singh *et al.*⁵³ The attempt to perform a nucleophilic substitution (S_N2), intended to transform the carbasugar **21** into the entecavir analog **22** failed, leading instead to the addition of the nucleobase in the β position and migration of the double bond to afford compound **23** (Scheme 6); however, MR starting from **24** gave compound **22** in 65% yield.




Scheme 6. Nucleobase β -addition with migration of double bond, a competitive reaction to the proposed $\text{S}_{\text{N}}2$ substitution, as reported by Singh *et al.*⁵³

MR was successfully used by Douadi *et al.*,⁵⁴ Christian *et al.*,⁵⁵ and Yang *et al.*⁵⁶ to afford nucleoside analogs **26**, **28** and **30**, starting from carbasugar substrates embodying a cyclopent-2-en-1-ol (Scheme 7), while palladium-catalyzed allylic substitution, one of the most common procedures for nucleobase coupling, did not produce the desired carbocyclic nucleoside. MR is also an alternative to nucleophilic substitution of unstable tosylated and mesylated substrates.⁵²



Scheme 7. MR coupling to cyclopentene derivatives as an alternative to Pd(0) catalyzed acetyl displacement, as described by Douadi *et al.*⁵⁴ (A), Christian *et al.*⁵⁵ (B) and Yang *et al.*⁵⁶ (C).

Failure to couple nucleobases to epoxides for the synthesis of isonucleosides type **34** encouraged Yoshimura *et al.* to treat the epoxide with thiophenol⁵⁷ or (4-methoxyphenyl)methanethiol⁵⁸ giving compounds type **32**, which were then submitted to MR. Stereoselective attack of the nucleobase to the episulfonium intermediate type **33** gave the nucleoside analog **34** (Scheme 8). Both 6-chloropurine and 3-benzoylthymine were successfully coupled by this methodology in good yields (83%-80% for 6-chloropurine and 52%-59% for 3-benzoylthymine).



Scheme 8. Nucleobase coupling by MR *via* episulfonium intermediate **33**, performed by Yoshimura *et al.*^{57,58}


3. Purine Coupling

The direct MR coupling of the two canonical purine nucleobases, adenine and guanine, is not, in most cases, the most applied methodology for nucleoside analog synthesis. Although adenine has been used as a pronucleophile,^{43,59-62} the strategy to obtain an adenine nucleoside relies mainly on the coupling of a nucleobase precursor, followed by transformation of the purine to adenine moiety.

No examples of successful coupling of guanine have been reported in the last ten years, as it does not react under the conditions producing moderate yields with other nucleobases,^{52,31,36} which may result from guanine's extremely low solubility,³⁶ even under reflux conditions.³¹


3.1. Adenine and adenine precursors' coupling

Like guanine, adenine also has a low solubility in THF.⁴⁰ Alternatively, 1,4-dioxane can be used as solvent in MR with this nucleobase, allowing for moderately good coupling yields when reacting with primary alcohols of carbasugar analogs. Illustrative examples were reported by Csuk & Thiedee,⁵⁹ who obtained the nucleoside analog **36** in 72% yield when coupling adenine to the difluorocyclopropane derivate **35**, and by Franzyk & Stermitz,⁶⁰ with the preparation of the carbocyclic nucleoside **38** in 68.5 % yield (Scheme 9).




Scheme 9. Successful coupling of adenine as reported by Csuk & Thiedee⁵⁹ (A), and Franzyk & Stermitz⁶⁰ (B).

Nevertheless, in most recent reports, alternative pronucleophiles have been used to obtain adenine nucleoside analogs, namely 6-chloropurine and 6-[bis(*tert*-butoxycarbonyl)amino]purine (Scheme 10).




Scheme 10. Structure of adenine precursors used in MR.

Both nucleobases led to moderate to good MR yields. Michael & Strazewski⁶³ succeeded to couple the two pronucleophiles to carbasugar **39**, obtaining compounds **40** and **42** in 82% and 95% yield, respectively (Scheme 11). However, sugar deprotection of **40** with TFA gave the unexpected hypoxanthine derivative **41**. Another example of Boc-protected 6-aminopurine coupling was reported by Liu *et al.*,⁶⁴ who coupled this nucleobase derivative to carbasugars **43**, **44** and **45** affording the nucleoside analogs in 77%, 87% and 88%, respectively (Scheme 12).



Scheme 11. High yield coupling of adenine precursors to a bicyclic carbasugar, and the formation of hypoxanthine derivative **41**, as described by Michael & Strazewski *et al.*⁶³



Scheme 12. High yield coupling of Boc-protected 6-aminopurine to three different secondary alcohols, as reported by Liu *et al.*⁶⁴


Both nucleobase derivatives, when linked to the sugar moiety, can be converted to give the corresponding adenine nucleosides. Reaction of 6-chloropurine to adenine requires high temperatures in methanolic NH_3 , commonly in high pressure vessels,⁴⁰ harsher reaction conditions than those for deprotection of 6-[bis(*tert*-butoxycarbonyl)amino]purine achieved at room temperature.⁶⁵ Moreover, 6-chloropurine is sensible to acid media, as reported by Michael & Strazewski,⁶³ leading to hypoxanthine derivatives, e.g. compound **41** (Scheme

11). Nevertheless, 6-chloropurine is quite used for nucleoside analog synthesis as it can be transformed into a variety of nucleobases, and in some cases gives better yields than the Boc-protected 6-aminopurine, as reported by Guo *et al.* for its coupling with *N*-protected L-serine methyl ester.²⁷


3.2. Guanine precursors' coupling

Guanine nucleoside analogs are frequently prepared by coupling 2-amino-6-chloropurine and derivatives, namely 2-acetamido-6-chloropurine,⁴⁴ 2-(*tert*-butoxycarbonyl)amino-6-chloropurine³³ and 2-[bis(*tert*-butoxycarbonyl)amino]-6-chloropurine, followed by acid⁶⁶ or basic treatment.⁶⁷

Mohamed *et al.*⁶⁵ achieved the coupling of 2-amino-6-chloropurine to a carbocyclic vinylphosphonate by MR to give the corresponding nucleoside analog in 80% yield, which was transformed in the carbocyclic vinylphosphonate derivative of guanine. Also, Miralles-Llumà *et al.*⁶⁶ took advantage of MR to couple this nucleobase to a cyclobutyl unit obtaining **47** in 87% yield. However the same nucleobase failed to couple with the alcohol **48**, but with the 2-[bis(*tert*-butoxycarbonyl)amino]-6-chloropurine, MR coupling generated the nucleoside analog **50** in 60% yield (Scheme 13). The versatility of 2-amino-6-chloropurine was also shown by Weising *et al.*,⁶⁷ who converted the carbocyclic nucleoside **51** into abacavir and carbovir (two antiviral drugs) in a single step (Scheme 14).




Scheme 13. Coupling of guanine precursors to two different carbasugars has been reported by Miralles-Llumà *et al.*⁶⁶




Scheme 14. High yield, one step conversion of **51** into the antiviral compounds abacavir and carbovir.⁶⁷

An alternative to chlorinated guanine precursors is a nucleobase embodying a diphenylcarbamate at position 6 with its 2-amino group protected with the 2-methylethylcarbonyl group. This guanine precursor was coupled to the diprotected glycerol **52** by Krishnamurthy *et al.*⁶⁸ via MR in yields ranging from 47% to 58% (Scheme 15). This acyclic nucleoside, derived from glycerol, was prepared for its further exploration in oligonucleotide chemistry aiming to discover new nucleic acid mimetics with base-pairing properties.



Scheme 15. Synthesis of the acyclic sugar nucleoside analog **53** derived from 1,3-diprotected glycerol **52** via MR.⁶⁸

Hollenstein & Leumann⁶⁹ succeeded to couple the same nucleobase to the acyclic diol **54** through a highly regioselective MR, affording the acyclic nucleoside analog **55** in 59% yield (Scheme 16). This structure served as a precursor to access new DNA mimetics with potential binding affinity to complementary oligonucleotides.



Scheme 16. Synthesis of acyclic nucleoside **55** as reported by Hollenstein & Leumann.⁶⁹


A similar purine was proposed by Lu *et al.*,³¹ with an acetamido group at position 2, which has a good solubility in THF and high reactivity. The authors succeeded to couple this protected nucleobase with primary, secondary and aromatic alcohols by MR in yields ranging from 70% to 80%.³¹ This base was also linked through MR to alkyl chains by Wamberg *et al.*,³⁴ aiming to generate new molecules for noncovalent anchoring to amphiphilic membranes. While these two examples do not describe nucleoside analog synthesis, they illustrate N⁹-guanine alkylation through MR and may therefore be potentially useful for the synthesis of isonucleoside, carbocyclic nucleosides and acyclic nucleosides.

3.3. Regioselectivity and alkylation of purine amino groups

Purine coupling to carbohydrates and carbasugars through MR is regioselective for the N⁹ position of the nucleobase, with only some rare examples of formation of N⁷-linked carbocyclic nucleosides as minor products,⁷⁰⁻⁷² and one report of N³ coupling as a major product in isonucleoside synthesis, with both adenine and 8-azaadenine as pronucleophiles.⁷³

MR regioselectivity conducting to the N⁹ linkage has also been found in acyclic nucleosides. An example is the reaction of bis[(*tert*-butylcarbonyloxy)methyl] 4-hydroxy-but-2-enylphosphonate with 6-chloropurine or 2-amino-6-chloropurine, affording, under MR conditions, the N⁹ acyclic nucleosides in 74% and 50% yield, respectively,⁷⁴ while a 21% N⁹:N⁷ (7:3) reaction mixture was obtained when the corresponding 4-bromo derivative reacted with the base by a S_N2 reaction.⁷⁴ However, some reports show that, even under MR conditions, the regioselectivity for the N⁹ isomer can be rather low, reaching proportions of N⁹/N⁷ (5.6:1), as shown by Manvar & Shah²⁶ for the coupling of 2-amino-6-chloropurine to the terminal hydroxy group linked to the ethoxymethylphosphonate chain. N⁹ regioselectivity was also described by Lu *et al.*³¹ in the synthesis of non-sugar carbon nucleosides through MR, although N⁷-alkylation also occurred when 2,6-dichloropurine was coupled to some of the alcohols, in 5-18% yields. Solvent, reaction temperature, azodicarboxylate reagent (DEAD or DIAD), and amount of non-limiting reagents also influence regioselectivity. Both Lu *et al.*³¹ and Manvar & Shah²⁶ described that, by adding alcohol (1.05 equiv.), DIAD (1.05 equiv.) and PPh₃ (1.05 equiv.) twice, and running the reaction for 6 hours after each addition, almost exclusively N⁹ alkylation occurred, while adding the same reagents' amount but in one single portion gave lower regioselectivity [22.3:1 (N⁹: N⁷)] and lower yields.^{26,31}

While most examples of purine alkylation through MR happen in the nucleobase N⁹ and N⁷ positions, the latter as minor reaction products, there is also the possibility of using MR to alkylate other positions of the purine. MR is highly chemoselective conducting to reaction at the N⁹ position, even with bases bearing a free amino group, namely 2-aminochloropurines. However, alkylation of the 2-amino group of N⁹-protected nucleobases was carried out by MR when using an excess of primary and secondary alcohols to give compounds type **57**, in high yields (86-93%).⁷⁵ Alkylation of the (*tert*-butoxycarbonyl)amino group in position 6 of the adenine derivative **58** by MR, with both primary and secondary alcohols, also gave nucleoside analogs in high yields (81-91%), deprotected by acid treatment (Scheme 17).⁷⁶ Noteworthy, these MRs only succeeded because the amino group is Boc-protected, which increases the acidity of this non-aromatic NH group.




Scheme 17. Alkylation of the 2-amino group and the 6-amino group, of guanine and adenine analogs, respectively, as presented by Fletcher *et al.*^{75,76}

4. Pyrimidine Coupling

The coupling of pyrimidines by MR is mostly restricted to 3-benzoyluracil and 3-benzoylthymine, which behave similarly as pronucleophiles. Cytosine is not commonly used, although some derivatives, in which the amino group is protected with a benzoyl group,⁷⁷ an acetyl group²⁷ or diprotected with bis(*tert*-butoxycarbonyl)⁷⁸ have been coupled with moderate to good yields.


4.1. N¹/O-2 Regioselectivity

MR regioselectivity is the main issue when the pronucleophile is a pyrimidine. Pyrimidines may undergo tautomerization in solution, as shown in Scheme 18. Since both NH and OH groups can act as pronucleophiles in MR, the use of this reaction with pyrimidines will usually result in mixtures of *N*-alkylated and *O*-alkylated products. Moreover, it is necessary to protect the N³ position, usually with a benzoyl group, to avoid linkage to N³ and O-4, which can result in the formation of nucleoside analogs embodying two sugar moieties.^{79,80}



Scheme 18. Tautomerization of uracil and thymine derivatives.

The regioselectivity of the reaction depends on multiple factors. Leung *et al.*,⁸¹ carried out the optimization of the MR experimental procedure for the coupling of N³-benzoylthymine to cyclopentanol **60** (Scheme 19, Table 1) by testing different solvents, reagent proportions and reaction temperature (0 °C and rt). The results showed that the highest regioselectivity and the highest yield for N¹-alkylation occurred by using DMF as solvent, in comparison with THF and dichloromethane (solvent as the only variable). It was also shown that, by increasing the proportion of the nucleobase relatively to the reagents Ph₃P and DIAD, at room temperature, the N¹-alkylated product yield increased from 53% to 64%, although at the cost of producing more of O-2 linked product, which yield increased from 8% to 25%.⁸¹



Scheme 19. 3-Benzoylthymine coupling performed by Leung *et al.*⁸¹

Table 1. Reaction optimization performed by Leung *et al.*⁸¹

PPh ₃ /DIAD (equiv.)	3-Benzoylthymine (equiv.)	Solvent	T (°C)	61 Yield (%)	62 Yield (%)
2.5	1.5	CH ₂ Cl ₂	rt	49	35
2.5	1.5	THF	rt	47	22
2.5	1.5	DMF	rt	53	8
2.5	1.5	DMF	0	33	12
1.5	3	DMF	0	48	20
1.5	3	DMF	rt	64	25


Weising *et al.*²⁹ tested MeCN and THF for the coupling of a carbocyclic *ribo*-nucleoside with analog N³-benzoylthymine, to control regioselectivity and avoid elimination. The results obtained show that in MeCN a product ratio of 1:1 (N¹:O-2) was obtained, while in THF the ratio was 1:4 (N¹:O-2), favoring O-2 ligation. This conclusion should be envisioned as specific for this reaction, as there are examples of regioselective N¹ coupling by MR with THF.⁷⁸

While in many cases the yield of MR with pyrimidines is quite good,^{23,59,75-77} there are no reported cases of nearly quantitative yields of N¹-linked products, most probably due to the formation of O-2 derivatives.


5. Coupling of Other Nitrogen Heterocycles

MR can be employed to synthesize carbocyclic nucleosides comprising *N*-heterocyclic bases with a structure not derived from canonical nucleobases, namely deazapurines. These compounds, including 1-deazapurines,⁸⁵ 3-deazapurines^{49,51,86-88} and 7-deazapurines⁴⁴ have been successfully coupled to alcohols by MR.

Unlike regular purines, the coupling of 3-deazapurine may not be regioselective. Yang *et al.*⁸⁷ reported an example where alcohol precursors with unsaturated bonds (compounds **63**, **64** and **65**, Scheme 20) led to N⁹ and N⁷ linked isomers, when 3-deaza-6-chloropurine was used as a pronucleophile. However, this regioselectivity may change when the base embodies bulky substituents that produce stereochemical hindrance to the attack of a particular position, as shown by Jha *et al.*⁴⁹ for the N⁷ position (Scheme 21). The authors obtained the N⁹ carbocyclic nucleoside by reaction of the carbasugar **66** with very minor formation of the N⁷ isomer (<5-7%).




Scheme 20. Non-regioselective coupling of 6-chloro-3-deazapurine to alcohols, as reported by Yang *et al.*⁸⁷



Scheme 21. N⁹ Regioselective coupling of a 3-deazapurine to the carbasugar **66** resulting from stereochemical hindrance.

6-Azaauracil (**68**) is a pyrimidine analog that can be coupled by MR with high N¹ regioselectivity, even without benzylation of N³, unlike pyrimidines. The enhanced acidity of N¹ resulting from the adjacent N⁶ favored the synthesis of the desired carbocyclic nucleoside **70**. Sugar deprotection afforded **71** in 54% yield over the two steps (Scheme 22).⁸⁹




Scheme 22. Regioselective coupling of unprotected 6-azauracil as reported by Jin *et al.*⁸⁹

Pursuing the development of novel and selective inhibitors of phosphoribosyltransferase, an enzyme that is crucial for the survival of the parasite *Plasmodium falciparum*, Klejch *et al.*²⁸ attached a diversity of acyclic

phosphonates with a free hydroxy group to the antiviral drug favipiravir and to a 4-chlorinated allopurinol precursor *via* MR (Scheme 23). Experimental conditions were extensively investigated, e.g., reagents proportion, time, temperature, solvent, but the coupling of favipiravir occurred mainly in the O-2 position (49-90% isolated yields for different alcohol substrates), or exclusively in this position (Scheme 23), while the coupling of the chlorinated allopurinol precursor produced only the desired N⁹ regioisomer.²⁸


In the search for furanose and pyranose isonucleosides as potential cholinesterase inhibitors for Alzheimer's disease treatment, the purine theobromine (compound **77**) has also been coupled to different carbohydrate moieties by MR, with regioselective alkylation of N¹(Scheme 24).^{79,80,90}



Scheme 23. MR regioselectivity resulting from reaction of favipiravir and 4-chlorinated allopurinol with the OH group of acyclic phosphonates.


6. Microwave-assisted MR Coupling

Microwave-assisted MR (MW-MR) is often an alternative to shorten reaction time and improve reaction yield. One example relies on MR of theobromine **77** with the primary alcohol **76**. Under conventional conditions, the reaction was carried out for 48 h and gave a very low yield (16%) of the N¹-linked isonucleoside **78**. However, the yield increased to 44% after 30 min under microwave irradiation (Scheme 24). With the same strategy, it was also possible to couple adenine to carbohydrate **76** in 33% yield, while under conventional conditions no reaction occurred.⁸⁰



Scheme 24. Theobromine coupling by MR under conventional heating and microwave irradiation.⁸⁰


Carbocyclic nucleosides **80-83**, analogs of neplanocin, a natural product with potent antitumor and antiviral activities, were synthesized by Liao *et al.*⁴⁴ The MR yield for base coupling of these 7-deazapurines increased from 20-30% under conventional heating conditions for sixteen hours, to 40-50% after 1 minute under microwave irradiation (Scheme 25).



Scheme 25. Carbocyclic neplanocin analogs by MR under conventional conditions and by MW assisted MR.⁴⁴

Weising *et al.*²⁹ tested MR with THF and MeCN for pyrimidine coupling to the carbasugar **15**, in both conventional conditions and under microwave irradiation (100 W, 45 °C) (Scheme 26). Interestingly the yield of **84** was not significantly increased (from 18% to 20%, in MeCN), and the ratio N¹:O-2 was 1:1 in both reaction conditions. The same trend was shown for N³-benzoyluracil under MW assisted MR.²⁹ However, the use of the MW-MR made the purification of the products easier because a smaller excess of reagents was required. Under the same reaction conditions, the coupling of **15** to N-4 acetylcytosine by MW-MR afforded exclusively the O-2 linked nucleoside analog **86** in 70 % yield. MW-MR was also used to couple 6-chloropurine and 2-amino-6-chloropurine, and the N⁹-nucleoside analogs were obtained in 80% and 70% yield, respectively, when reaction was carried out in THF, as MeCN led to a lower yield (49%) for 6-chloropurine coupling with **15**.²⁹ Similar microwave-assisted conditions (100 W, 50 °C) were reported for the coupling of 2-amino-6-chloropurine to alcohol **87** in 59% yield after one hour.⁶⁷

These illustrative examples demonstrate that MW-MR may be a step forward for nucleobase coupling by giving considerably shorter reaction times, facilitating nucleoside analog purification, and in some instances also improving reaction yields.



Scheme 26. Microwave-assisted Mitsunobu reactions as reported by Weising *et al.*^{29,67}

7. Conclusions

Throughout this survey, multiple aspects affecting the synthesis of nucleoside analogs by MR were highlighted and discussed. Indeed, no single factor, by itself, can determine the success of the reaction, but some conclusions can be withdrawn. First, some alcohol precursors are not suitable for nucleobase coupling, due to their low reactivity, as the tertiary or highly hindered secondary alcohols, some of them suffering side reactions, e.g. elimination or β addition on α,β -unsaturated alcohols. Nucleobases with low solubility have a dramatic effect on yield, and reaction optimization is usually successful if a suitable solvent is found, or if the nucleobase is chemically modified. Some of the reaction parameters that can affect yields, such as temperature or order of addition of reagents, cannot be so easily rationalized, as they change depending on the substrate, pronucleophile, solvent and reagents. Thus, the data available in the literature do not allow any prediction or general recommendation to improve yields. This is particularly noteworthy when it comes to MR with the pyrimidines 3-benzoyluracil and 3-benzoylthymine. Even though both solvent and temperature affect the formation of the undesired O-2 coupled products, no exact conditions have been reported favoring N¹-alkylation; and base coupling conditions must be optimized case by case, aiming at a higher yield of the product resulting from N-ligation. Purine coupling is less problematic, due to MR N⁹ regioselectivity. N⁷-Ligation generates only minor products, and MR coupling with purines leads quite often to high yields of the N⁹ regioisomers, when appropriate alcohol precursors are used. MR was also applied to alkylate amino group substituents in adenine and guanine precursors, when nucleobase reactive functionality is protected.

Microwave-assisted MR is considerably faster than conventional ones, and in some cases lead to higher product yields, encouraging further developments in nucleoside analog synthesis with this green chemical approach.

MR has also been used for the coupling of unnatural nucleobases, such as deaza analogs of purines, 6-azauracil, as well as other aromatic nitrogen heterocycles, broadening the scope of its application. It is not our aim to present a comprehensive review on nucleoside base coupling by MR, but instead to highlight the benefits and the drawbacks found in the synthesis of nucleoside analogs, when the classical reactions for the nucleobase coupling do not succeed or give lower yields and regioselectivity. Nonetheless, by considering the numerous examples of the successful application of MR in the synthesis of carbocyclic nucleosides, acyclic nucleosides and isonucleosides, it can be concluded that MR is a viable experimental tool for the coupling of nucleobases to alcohols, opening the door to novel nucleoside analogs.

Acknowledgements

The authors are grateful to Fundação para a Ciência e a Tecnologia (FCT, Portugal) for the financial support to Centro de Química Estrutural (project UIDB/00100/2020).

References

1. Jordheim, L. P.; Durantel, D.; Zoulim, F.; Dumontet, C. *Nat. Rev. Drug Discov.* **2013**, *12*, 447–464.
<https://doi.org/10.1038/nrd4010>
2. Tsesmetzis, N.; Paulin, C. B. J.; Rudd, S. G.; Herold, N. *Cancers* **2018**, *10*, 240.
<https://doi.org/10.3390/cancers10070240>
3. Guinan, M.; Benckendorff, C.; Smith, M.; Miller, G. J. *Molecules* **2020**, *25*, 2050.
<https://doi.org/10.3390/molecules25092050>
4. Tino, J. A.; Clark, J. M.; Field, A. K.; Jacobs, G. A.; Li, K. A.; Michalik, T. L.; Mcgeever-rubin, B.; Slusarchyk, W. A.; Spergel, S. H.; Sundeen, J. E.; Tuomari, A. V.; Weaver, E. R.; Young, M. G.; Zahler, R. *J. Med. Chem.* **1993**, *36*, 1221-1229.
<https://doi.org/10.1021/jm00061a013>
5. Soike, K. F.; Huang, J. L.; Russel, J. W.; Whiterock, V. J.; Sundeen, J. E.; Stratton, L. W.; Clarkm, J. M. *Antiviral Res.* **1994**, *23*, 219-224.
[https://doi.org/10.1016/0166-3542\(94\)90019-1](https://doi.org/10.1016/0166-3542(94)90019-1)
6. Wang, J.; Rawal, R. K.; Chu, C. K. *In Medicinal Chemistry of Nucleic Acids* Zhang, L.-H., Xi, Z., Chattopadhyaya, J. Eds.; John Wiley & Sons, Inc; Hoboken, NJ, 2011; pp 1–100.
7. Crimmins, M. T.; *Tetrahedron* **1998**, *54*, 9229-9272.
[https://doi.org/10.1016/S0040-4020\(98\)00320-2](https://doi.org/10.1016/S0040-4020(98)00320-2)
8. Xie, M. S.; Niu, H. Y.; Qu, G. R.; Guo, H. M. *Tetrahedron Lett.* **2014**, *55*, 7156-7166.
<https://doi.org/10.1016/j.tetlet.2014.11.060>
9. Mitsunobu, O.; Yamada, M.; *Bull. Chem. Soc. Jpn.* **1967**, *40*, 2380-2382.
<https://doi.org/10.1246/bcsj.40.2380>
10. Swamy, K. C. K.; Kumar, N. N. B.; Balaraman, E.; Kumar, K. V. P. P. *Chem. Rev.* **2009**, *109*, 2551-2651
<https://doi.org/10.1021/cr800278z>
11. Fletcher, S. *Org. Chem. Front.* **2015**, *2*, 739-752.
<https://doi.org/10.1039/C5QO00016E>
12. Li, J. J. *Name Reactions*, 2nd Edn., Springer-Verlag, Heidelberg, 2003, p 265.

- https://doi.org/10.1007/978-3-662-05336-2_198
13. But, T. Y. S., Toy, P. H. *J. Am. Chem. Soc.* **2006**, *128*, 9636-9637.
<https://doi.org/10.1021/ja063141v>
14. But, T. Y. S. ; Lu, J. ; Toy, P. H. *Synlett* **2010**, 1115-1117.
<https://doi.org/10.1055/s-0029-1219795>
15. Hirose, D. ; Taniguchi, T., Ishibashi, H. *Angew. Chem. Int. Ed.* **2013**, *52*, 4613 – 4617.
<https://doi.org/10.1002/anie.201300153>
16. Hirose, D. ; Gazvoda, M. ; Janez Kosmrlj, J. ; Taniguchi, T. *Chem. Sci.* **2016**, *7*, 5148-5159.
<https://doi.org/10.1039/C6SC00308G>
17. Buonomo, J. A.; Aldrich, C. C. *Angew. Chem. Int. Ed.* **2015**, *54*, 13041-13044.
<https://doi.org/10.1002/anie.201506263>
18. Hirose, D. ; Gazvoda, M. ; Janez Kosmrlj, J. ; Taniguchi, T. *Org. Lett.* **2016**, *18*, 4036–4039.
<https://doi.org/10.1021/acs.orglett.6b01894>
19. Beddoe, R. H.; Andrews, H. G.; Magné, V.; Cuthbertson, J. D.; Shannon-Little, A. L.; Shanahan, S. E.; Sneddon, H. F.; Denton, R. M. *Science*, **2019**, *365*(6456), 910-914.
<https://doi.org/10.1126/science.aax3353>
20. Tănase, C. I.; Drăghici, C.; Hanganu, A.; Pintilie, L.; Maganu, M.; Volobueva, A.; Sinegubova, E.; Zarubaeu, V. V.; Neyts, J.; Jochmans, D.; Slita, A. V. *Molecules* **2019**, *24*, 2446.
<https://doi.org/10.3390/molecules24132446>
21. Gioti, E. G.; Koftis, T. V.; Neokosmidis, E.; Vastardi, E.; Kotoulas, S. S.; Trakossas, S.; Tsatsas, T.; Anagnostaki, E. E.; Panagiotidis, T. D.; Zacharis, C.; Tolika, E. P.; Varvogli, A. A.; Andreou, T.; Gallos, J. K. *Tetrahedron* **2018**, *74*, 519-527.
<https://doi.org/10.1016/j.tet.2017.12.034>
22. Velasco, J.; Ariza, X.; Badía, L.; Bartra, M.; Berenguer, R.; Farrás, J.; Gallardo, J.; Garcia, J.; Gasanz, Y. *J. Org. Chem.* **2013**, *78*, 5482-5491.
<https://doi.org/10.1021/jo400607v>
23. Xu, H.; Wang, F.; Xue, W.; Zheng, Y.; Wang, Q.; Qiu, F. G.; Jin, Y. *Org. Process Res. Dev.* **2018**, *22*, 377-384.
<https://doi.org/10.1021/acs.oprd.8b00007>
24. Beddoe, R. H.; Sneddon, H. F.; Denton, R. M.; *Org. Biomol. Chem.* **2018**, *16*, 7774-7781.
<https://doi.org/10.1039/C8OB01929K>
25. Ludek, O. R.; Krämer, T.; Balzarini, J.; Meier, C. *Synthesis* **2005**, *8*, 1313-1324.
26. Manvar, A.; Shah, A.; *Tetrahedron* **2013**, *69*, 680-691.
<https://doi.org/10.1016/j.tet.2012.10.079>
27. Guo, H. M.; Wu, Y. Y.; Niu, H. Y.; Wang, D. C.; Qu, G. R. *J. Org. Chem.* **2010**, *75*, 3863-3866.
<https://doi.org/10.1021/jo100397a>
28. Klejch, T.; Pohl, R.; Janeba, Z.; Sun, M.; Keough, D. T.; Guddat, L. W.; Hocková, D.; *Tetrahedron* **2018**, *74*, 5886-5897.
<https://doi.org/10.1016/j.tet.2018.08.014>
29. Weising, S.; Torquati, I.; Meier, C. *Synthesis* **2018**, *50*, 1264-1274.
<https://doi.org/10.1055/s-0036-1591732>
30. Jessel, S.; Meier, C. *Eur. J. Org. Chem.* **2011**, *2011*, 1702-1713.
<https://doi.org/10.1002/ejoc.201001473>
31. Lu, W.; Sengupta, S.; Petersen, J. L.; Akhmedov, N. G.; Shi, X. *J. Org. Chem.* **2007**, *72*, 5012-5015.
<https://doi.org/10.1021/jo070515+>

32. Dai, L. Y.; Shi, Q. L.; Zhang, J.; Wang, X. Z.; Chen, Y. Q. *J. Zhejiang Univ. Sci A* **2013**, *14*(10), 760-766.
<https://doi.org/10.1631/jzus.A1300238>
33. Fletcher, S.; Shahani, V. M.; Lough, A. J.; Gunning, P. T. *Tetrahedron* **2010**, *66*, 4621-4632.
<https://doi.org/10.1016/j.tet.2010.03.118>
34. Wamberg, M. C.; Pedersen, P. L.; Löffler, P. M. H.; Albertsen, A. N.; Maurer, S. E.; Nielsen, K. A.; Monnard, P. A. *Bioconjug. Chem.* **2017**, *28*, 1893-1905.
<https://doi.org/10.1021/acs.bioconjchem.7b00228>
35. Šála, M.; De Palma, A. M.; Hřebabecký, H.; Nencka, R.; Dračínský, M.; Leyssen, P.; Neyts, J.; Holý, A. *Bioorg. Med. Chem.* **2010**, *18*, 4374-4384.
<https://doi.org/10.1016/j.bmc.2010.04.081>
36. Chen, W.; Flavin, M. T.; Filler, R.; Xu, Z. Q. *J. Chem. Soc., Perkin Trans. 1* **1998**, *23*, 3979-3988.
<https://doi.org/10.1039/a805929b>
37. Brémond, P.; Audran, G.; Monti, H.; De Clercq, E. *Synthesis* **2008**, *20*, 3253-3260.
<https://doi.org/10.1055/s-0028-1083146>
38. Kasula, M.; Toyama, M.; Samunuri, R.; Rozy, F.; Yadav, M.; Bal, C.; Kumar, A.; Baba, M.; Sharon, A. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 3945-3949.
<https://doi.org/10.1016/j.bmcl.2016.07.005>
39. Rosen, T. C.; De Clercq, E.; Baizarini, J.; Haufe, G.; *Org. Biomol. Chem.* **2004**, *2*, 229-237.
<https://doi.org/10.1039/b310059f>
40. Yin, X.; Li, W.; Schneller, S. W. *Tetrahedron Lett.* **2006**, *47*, 9187-9189.
<https://doi.org/10.1016/j.tetlet.2006.10.126>
41. Fernández, P.; García-Mera, X.; López, C.; Morales, M.; Rodríguez-Borges, E. *Synthesis* **2005**, *20*, 3549-3554.
<https://doi.org/10.1055/s-2005-918420>
42. Bazile, Q.; Serbessa, T.; Zhong, J. *Tetrahedron Lett.* **2012**, *53*, 1435-1437.
<https://doi.org/10.1016/j.tetlet.2012.01.047>
43. Danappe, S.; Pal, A.; Alexandre, C.; Aubertin, A. *Tetrahedron* **2005**, *61*, 5782-5787.
<https://doi.org/10.1016/j.tet.2005.04.023>
44. Liao, X.; Butora, G.; Olsen, D. B.; Carroll, S. S.; McMaster, D. R.; Leone, J. F.; Stahlhut, M.; Doss, G. A.; Yang, L.; MacCoss, M. *Tetrahedron Lett.* **2008**, *49*, 4149-4152.
<https://doi.org/10.1016/j.tetlet.2008.04.115>
45. Kumamoto, H.; Haraguchi, K.; Ida, M.; Nakamura, K. T.; Kitagawa, Y.; Hamasaki, T.; Baba, M.; Simbara, S.; Tanaka, H. *Tetrahedron* **2009**, *65*, 7630-7637
46. Viña, D.; Santana, L.; Uriarte, E.; Terán, C. *Tetrahedron* **2005**, *61*, 473-478.
<https://doi.org/10.1016/j.tet.2004.10.076>
47. Aubin, Y.; Audran, G.; Monti, H.; De Clercq, E.; *Bioorg. Med. Chem.* **2008**, *16*, 374-381.
<https://doi.org/10.1016/j.bmc.2007.09.030>
48. Kumamoto, H.; Deguchi, K.; Wagata, T.; Furuya, Y.; Odanaka, Y.; Kitade, Y.; Tanaka, H. *Tetrahedron* **2009**, *65*, 8007-8013.
<https://doi.org/10.1016/j.tet.2009.07.039>
49. Jha, A. K.; Sharon, A.; Rondla, R.; Chu, C. K. *Tetrahedron* **2009**, *65*, 9362-9367.
<https://doi.org/10.1016/j.tet.2009.08.087>
50. Eid, A. A.; Koubeissi, A.; Bou-Mjahed, R.; Al Khalil, N.; Farah, M.; Maalouf, R.; Nasser, N.; Bouhadir, K. H. *Bioorg. Med. Chem Lett.* **2013**, *23*, 174-178.
<https://doi.org/10.1016/j.bmcl.2012.10.122>

51. Chen, C.; Ye, W.; Liu, C.; Schneller, S. W. *Tetrahedron* **2012**, *68*, 3908-3914.
<https://doi.org/10.1016/j.tet.2012.03.023>
52. Gouault-Bironneau, S.; Sène, A.; Catel, J. M.; Lequeaux, T. *J. Fluor. Chem.* **2008**, *129*, 848-851.
<https://doi.org/10.1016/j.jfluchem.2008.04.005>
53. Singh, U. S.; Mishra, R. C.; Shankar, R.; Chu, C. K.; *J. Org. Chem.* **2014**, *79*, 3917-3923.
<https://doi.org/10.1021/jo500382v>
54. Douadi A.; Brémond, P.; Lanez, T.; Pannecouque C.; Audran, G. *Synlett* **2011**, *1*, 111-115.
55. Christian, P.; Uttaro, J.; Broussous, S.; Math, C.; Périgaud, C. *Tetrahedron* **2013**, *69*, 2131-2136.
<https://doi.org/10.1016/j.tet.2013.01.011>
56. Yang, Y.; Zheng, F.; Qing, F.; *Tetrahedron* **2011**, *67*, 3388-3394.
<https://doi.org/10.1016/j.tet.2011.03.054>
57. Yoshimura, Y.; Asumi, K.; Matsui, H.; Tanaka, H. *Org. Lett.* **2006**, *8*, 6015-6018.
<https://doi.org/10.1021/ol062491j>
58. Yoshimura, Y.; Asumi, K.; Imamichi, T.; Okuda, T.; Shiraki, K.; Takahata, H. *J. Org. Chem.* **2010**, *75*, 4161-4171.
<https://doi.org/10.1021/jo100556u>
59. Csuk, R.; Thiedee, G. *Tetrahedron* **1999**, *55*, 739-750.
[https://doi.org/10.1016/S0040-4020\(98\)01067-9](https://doi.org/10.1016/S0040-4020(98)01067-9)
60. Franzyk, H.; Stermitz, F. R. *J. Nat. Prod.* **1999**, *62*, 1646-1654.
<https://doi.org/10.1021/np990288+>
61. Wang, J.; Viña, D.; Busson, R.; Herdewijn, P. *J. Org. Chem.* **2003**, *68*, 4499-4505.
<https://doi.org/10.1021/jo0300946>
62. Danappe, S.; Boeda, R.; Alexandre, C.; Aubertin, A. M.; Bourgoungnon, N.; Huet, F. *Synth. Commun.* **2006**, *36*, 3225-3239.
<https://doi.org/10.1080/00397910600908918>
63. Michael, B. Y.; Strazewski, P. *Chem. Eur. J.* **2009**, *15*, 6244-6257.
<https://doi.org/10.1002/chem.200802629>
64. Liu, C.; Chen, Q.; Schneller, S. W.; *Tetrahedron Lett.* **2011**, *52*, 4931-4933.
<https://doi.org/10.1016/j.tetlet.2011.07.059>
65. Mohamed, B. S.; Périgaud, C.; Peyrottes, S.; Uttaro, J.; Mathé, C. *New J. Chem.* **2018**, *42*, 974-979.
<https://doi.org/10.1039/C7NJ03991C>
66. Miralles-Llumà, R.; Figueras, A.; Busqué, F.; Alvarez-Larena, A.; Balzarini, J.; Figueredo, M.; Font, J.; Alibés, R.; Maréchal, J. *Eur. J. Org. Chem.* **2013**, *2013*, 7761-7775.
<https://doi.org/10.1002/ejoc.201301097>
67. Weising, S.; Sterreberg, V.; Schols, D.; Meier, C. *ChemMedChem* **2018**, *13*, 1771-1778.
<https://doi.org/10.1002/cmdc.201800361>
68. Kim, K.; Punna, V.; Karri, P.; Krishnamurthy, R. *Beilstein J. Org. Chem.* **2014**, *10*, 2131-2138.
<https://doi.org/10.3762/bjoc.10.220>
69. Hollenstein, M.; Leumann, C. J. *J. Org. Chem.* **2005**, *70*, 3205-3217.
<https://doi.org/10.1021/jo047753e>
70. Reichardt, B.; Meier, C. *Nucleosides Nucleotides and Nucleic Acids* **2007**, *26*, 935-937.
<https://doi.org/10.1080/15257770701507937>
71. Kumamoto, H.; Takahashi, N.; Shimamura, T.; Tanaka, H.; Nakamura, K. T.; Hamasaki, T.; Baba, M.; Abe, H.; Yano, M.; Kato, N. *Tetrahedron* **2008**, *64*, 1494-1505.

- <https://doi.org/10.1016/j.tet.2007.11.038>
72. Mohamed, B. S.; Périgaud, C.; Mathé, C. *Beilstein J. Org. Chem.* **2017**, *13*, 251-256.
<https://doi.org/10.3762/bjoc.13.28>
73. Bera, S.; Nair, V. *Helv. Chim. Acta* **2000**, *83*, 1398-1407.
[https://doi.org/10.1002/1522-2675\(20000705\)83:7<1398::AID-HLCA1398>3.0.CO;2-I](https://doi.org/10.1002/1522-2675(20000705)83:7<1398::AID-HLCA1398>3.0.CO;2-I)
74. Pradère, U.; Roy, V.; Montagu, A.; Sari, O.; Hamada, M.; Balzarini, J.; Snoeck, R.; Andrei, G.; Agrofoglio, L. A. *Eur. J. Med. Chem.* **2012**, *57*, 126-133.
<https://doi.org/10.1016/j.ejmech.2012.08.042>
75. Fletcher, S.; Shahani, V. M.; Gunning, P. T. *Tetrahedron Lett.* **2009**, *50*, 4258-4261.
<https://doi.org/10.1016/j.tetlet.2009.04.137>
76. Fletcher, S. *Tetrahedron Lett.* **2010**, *51*, 2948-2950.
<https://doi.org/10.1016/j.tetlet.2010.03.103>
77. Alexander, P.; Krishnamurthy, V.; Prisbe, E. J. *J. Med. Chem.* **1996**, *39*, 1321-1330.
<https://doi.org/10.1021/jm950788+>
78. John, J.; Kim, Y.; Bennet, N.; Das, K.; Liekens, S.; Naesens, L.; Arnold, E.; Maguire, A. R.; Götte, M.; Dehaen, W.; Balzarini, J. *J. Med. Chem.* **2015**, *58*, 8110-8127.
<https://doi.org/10.1021/acs.jmedchem.5b01180>
79. Batista, D.; Schwarz, S.; Loesche, A.; Csuk, R.; Costa, P. J.; Oliveira, M. C.; Xavier, N. M. *Pure Appl. Chem.* **2016**, *88*, 363-379.
<https://doi.org/10.1515/pac-2016-0102>
80. Xavier, N. M.; de Sousa, E. C.; Pereira, M. P.; Loesche, A.; Serbian, I.; Csuk, R.; Conceição, M. *Pharmaceuticals* **2019**, *12*, 103.
<https://doi.org/10.3390/ph12030103>
81. Leung, L. M. H.; Gibson, V.; Linclau, B. *J. Org. Chem.* **2008**, *73*, 9197-9206.
<https://doi.org/10.1021/jo801848h>
82. Elhalem E.; Pujol, C. A.; Damonte, E. B.; Rodriguez, J. B. *Tetrahedron* **2010**, *66*, 3332-3340.
<https://doi.org/10.1016/j.tet.2010.02.092>
83. Kumamoto, H.; Kobayashi, M.; Kato, N.; Balzarini, J.; Tanaka, H. *Eur. J. Org. Chem.* **2011**, *2011*, 2685-2691.
<https://doi.org/10.1002/ejoc.201100062>
84. Mahler, M.; Reichardt, B.; Hartjen, P.; van Lunzen, J.; Meier, C. *Chem. Eur. J.* **2012**, *18*, 11046-11062.
<https://doi.org/10.1002/chem.201200733>
85. Tosh, D. K.; Crane, S.; Chen, Z.; Paoletta, S.; Gao, Z. G.; Gizewski, E.; Auchampach, J. A.; Salvemini, D.; Jacobson, K. A. *ACS Med. Chem. Lett.* **2015**, *6*, 804-808.
<https://doi.org/10.1021/acsmedchemlett.5b00150>
86. Yang, M.; Zhou, J.; Schneller, S. W. *Tetrahedron Lett.* **2004**, *45*, 8981-8982.
<https://doi.org/10.1016/j.tetlet.2004.10.052>
87. Yang, M.; Zhou, J.; Schneller, S. W. *Tetrahedron* **2006**, *62*, 1295-1300.
<https://doi.org/10.1016/j.tet.2005.10.052>
88. Chen, Q.; Liu, C.; Komazin, G.; Bowlin, T. L.; Schneller, S. W. *Bioorg. Med. Chem.* **2014**, *22*, 6961-6964.
<https://doi.org/10.1016/j.bmc.2014.10.014>
89. Jin, Y. H.; Liu, P.; Wang, J.; Baker, R.; Huggins, J.; Chu, C. K.; *J. Org. Chem.* **2003**, *68*, 9012-9018.
<https://doi.org/10.1021/jo034999v>
90. Gonçalves-Pereira, R.; Pereira, M. P.; Serra, S. G.; Loesche, A.; Csuk, R.; Silvestre, S.; Costa, P. J.; Oliveira, M. C.; Xavier, N. M. *Eur. J. Org. Chem.* **2018**, *2018*, 2667-2681.

<https://doi.org/10.1002/ejoc.201800245>

Authors' Biography



Eduardo C. de Sousa was born in Torres Vedras, Portugal, in 1997, and started his higher education in Lisbon, receiving his BSc degree in Chemistry in 2018 from Faculdade de Ciências, Universidade de Lisboa (CiênciasUL) with the graduation project on the synthesis of novel isonucleos(t)ides, receiving the final mark of 20/20, under supervision of Dr. Nuno Xavier, which results were published in *Pharmaceuticals* in 2019. He is currently finishing his MSc dissertation at the Carbohydrate Chemistry Group, Centro de Química Estrutural (CQE), under the supervision of Prof. Amélia Pilar Rauter, which included a six month internship at Max Plank Institute of Colloids and Interfaces, Biomolecular Systems Department, supervised by Dr. Daniel Varon Silva. His main research interest is carbohydrate synthetic chemistry.



Amélia Pilar Rauter is Full Professor of Organic Chemistry, Department of Chemistry and Biochemistry, at Faculdade de Ciências, Universidade de Lisboa (CiênciasUL) (recently retired). She is the President of the International Carbohydrate Organisation and the Secretary of the European Carbohydrate Organisation, and serves IUPAC as Vice-President of the IUPAC Division on Organic and Biomolecular Chemistry, as Titular

Member of IUPAC Division of Chemical Nomenclature and Structure Representation, and as Associate Member of its Interdivisional Committee on Terminology, Nomenclature and Symbols. She is the founder of the Portuguese Chemical Society Carbohydrate Chemistry Group, and the founder and leader of the Centro de Química Estrutural (CQE) Carbohydrate Chemistry Group. Her research covers the design and synthesis of new leads for diabetes, degenerative diseases (Alzheimer's and Prion diseases, cancer), and infection. Among her honors, she was awarded with the Madinaveitia-Lourenço Prize by the Spanish Royal Chemical Society, is Fellow of the Royal Society of Chemistry, and Chemistry Europe Fellow. At the national level she was awarded with the Mention of Excellency in all curricular evaluations since 2007 by CiênciasUL.

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)